Revised. Amendments from Version 1
==================================

We have adapted our manuscript according to the reviewers' comments. In addition to providing a response to each reviewer's comment on the web page, we have made to following changes to the paper: In the data analysis methods paragraph, we explained why a list of 22 studies appeared in tables and figures, while only 21 studies were included in the meta-analysis: the Blanco study provided two study populations with different treatment strategies.In table 2, we corrected two minor typos.In the drug resistance results paragraph, we clarified the characteristics of the subjects that developed InSTI mutations.In the discussion section, we made the following slight changes: inclusion of information on virological failure rates in trials evaluating InSTI-based triple maintenance combinations and on the activity of DTG-based simplified regimens in compartments other than blood; replacement of the XTC acronym by 3TC or FTC; inclusion of two references on the impact of the 184V mutation on viral fitness.

Introduction
============

The concept of combination antiretroviral therapy (ART) for the treatment of HIV infection was established twenty years ago, when the results of the first studies evaluating protease inhibitor-based regimens were published ^[@ref-1]^. In recent years, several strategies of treatment optimization and simplification gained interest, with the objectives of improving quality of life, minimizing ART-related toxicity and drug-drug interactions (DDI), as well as reducing health-related costs. So far, ART de-escalation from three to one (mono-) or two drugs (dual-) therapies has mainly been evaluated in virologically suppressed patients. The first simplified maintenance strategy studied included a boosted protease inhibitor (bPI), with the hope that the high genetic barrier to resistance would help achieve durable virological suppression. In a meta-analysis including ten studies, bPI monotherapy was found to be inferior to triple ART for the maintenance of viral suppression ^[@ref-2]^, but non-inferior with regards to loss of future treatment options ^[@ref-3]^. In contrast, dual therapy with bPI and lamivudine (3TC) was found to be non-inferior to triple ART ^[@ref-4]--\ [@ref-6]^ and is now recognized as a valid switch strategy by current HIV treatment guidelines in selected situations ^[@ref-7]^. However, bPI-based maintenance strategies are not widely applicable because of cost, toxicity and DDI.

Due to its interesting pharmacokinetic profile, good tolerability and high barrier to resistance, dolutegravir (DTG), a new integrase strand transfer inhibitor (InSTI), has attracted much interest for its use in simplified treatment regimens. While preliminary analyses of a Dutch DTG monotherapy simplification trial seemed encouraging at 24 weeks, rates of virological failures increased significantly by week 48, suggesting a sub-optimal potency of this regimen ^[@ref-8]^. On the other hand, several studies evaluating DTG-based dual therapy with either 3TC or rilpivirine (RPV), showed a high virological efficacy ^[@ref-9]--\ [@ref-12]^. However, most reports were from small, observational cohort studies, with the exception of one DTG-RPV industry-sponsored randomized controlled trial (RCT) ^[@ref-11]^.

We performed a systematic review of the literature and a meta-analysis to provide precise estimates of the rate of virological failure (VF) and drug resistance in patients switched to a DTG-based maintenance mono- or dual therapy, and to clarify which drugs or combinations should be evaluated in further studies and implemented in clinical practice.

Methods
=======

The protocol for this systematic review was written and registered with the International Prospective Register of Systematic Reviews (PROSPERO registration number [CRD42017070045](https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=70045)) ^[@ref-13]^. The reporting of the review followed the PRISMA guidelines ^[@ref-14]^ ( [Supplementary File 1](#SF1){ref-type="other"}).

Search strategy and selection criteria
--------------------------------------

We searched Medline, EMBASE, Cochrane Central and Web of Science, as well as abstracts of major HIV conferences (CROI, AIDS, HIV Glasgow, AFRAVIH, IAS and EACS between 2013 and 2017) on 4. January 2018 for studies assessing the proportion of individuals developing VF on DTG-based maintenance therapy. In Medline we combined free text words and medical subject headings (MESH) describing the study population and the outcome ( [Supplementary File 2](#SF2){ref-type="other"}). This search strategy was adapted for the other databases. We considered RCTs, single-arm clinical trials, cohort studies, and case-series that included at least five HIV-infected adults (≥18 years) on DTG-based simplified therapy. No language restrictions were applied. Studies had to report on virological outcomes of patients who switched to a DTG monotherapy or dual therapy after having an undetectable VL on triple ART. We excluded studies that only reported *in vitro* data and those selecting participants based on the outcome during DTG-based maintenance therapy. Two investigators (MB and GW) independently selected studies based on titles and abstracts, and, in a second step, based on the full text of potentially eligible articles. Discrepancies in study selection were resolved through discussions with a third investigator (AC).

Data extraction
---------------

The following data were extracted independently for each study by two reviewers (GW and MB), using a standardized spreadsheet: bibliographic details, study design, inclusion and exclusion criteria, definitions of outcomes, country, number of participants and their main demographic and clinical characteristics, including duration since HIV diagnosis, ART history, immunological status (CD4 cell count at switch and nadir) and virological parameters (HIV RNA peak and at baseline, HIV-DNA at baseline and changes during the study, VF as defined by the study, and the presence at drug resistance at switch). Again, discrepancies in data extracted were resolved through discussions with a third investigator (AC).

Assessment of risk of bias
--------------------------

A checklist for the assessment of risk of bias was designed to ensure data quality assessment for each study was included. The form for RCTs included information on the sequence generation, allocation concealment, blinding (participants, personnel and outcome assessor), incomplete outcome data, selective outcome reporting and other sources of bias. The methodological components of the randomized trials were assessed by two independent authors and classified as high, low or unclear risk of bias, as recommended by the Cochrane collaboration ^[@ref-15]^. For observational studies it was not appropriate to use the ROBINS-I tool ^[@ref-16]^, as we only considered data from the group of patients on simplified, maintenance therapy. Thus, we assessed the population characteristics and missing outcome data for each study.

Data analysis
-------------

We described the study design as well as the demographic and clinical characteristics of the population from each study by type of maintenance therapy (DTG-based monotherapy or dual therapy). Pooled proportions of VF and treatment failure (VF or departure from simplified strategy due to toxicity, loss to follow-up, patient's or physician's decision), and 95% confidence intervals (CI) were estimated using random intercept logistic meta-regression. These analyses were performed separately at 24 weeks and 48 weeks after the switch from triple ART to maintenance therapy. For all models, statistical evidence for heterogeneity between studies was assessed using the tau-squared statistics ^[@ref-17]^. Of note, we separated data from Blanco *et al.* ^[@ref-18]^ according to the strategy used (DTG-monotherapy and DTG-based dual therapy). We evaluated the association between type of maintenance strategy and VF using random intercept logistic meta-regression (binomial-normal) models. All models were adjusted for potential confounders, including age (median or mean), sex (proportion of female participants) and study type (interventional or observational). Furthermore, the proportion of participants acquiring new drug resistance mutations was assessed for each treatment strategy and the mutations described in detail. Statistical analyses were conducted in STATA version 14.1 (StataCorp, Texas, USA) and R version 3.2.3 (R Core Team, Vienna, Austria).

Role of the funding source
--------------------------

The funder of the study had no role in the design, data collection, data analysis, data interpretation of the results or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results
=======

Study and participant characteristics
-------------------------------------

Of 1719 single studies identified, 63 remained potentially eligible after the screening of titles and abstracts. Of these, 21 studies, including four RCTs, three single-arm clinical trials and 14 observational studies met our inclusion criteria ^[@ref-8],\ [@ref-11],\ [@ref-12],\ [@ref-18]--\ [@ref-35]^ ( [Figure 1](#f1){ref-type="fig"}). A description of the main study characteristics by type of maintenance strategy is given in [Table 1](#T1){ref-type="table"}. Eight studies (two from France, two from The Netherlands, one from Germany, one from Switzerland and two from Spain) including 251 patients assessed the switch to DTG monotherapy and 14 (five from Italy, four from France, three for Spain, one from US, and one multi-country study), including 1670 participants, the switch to DTG-based dual therapy. Dual therapy consisted of DTG + 3TC (seven studies) or RPV (four studies) or atazanavir (ATV, two studies) or darunavir (DRV, one study). Overall, 14 studies allowed the inclusion of patients with previous virological failure, including five monotherapy studies ^[@ref-18]--\ [@ref-20],\ [@ref-22]--\ [@ref-24]^. In one study, patients with previous InSTI failure were also included ^[@ref-12]^. Nineteen studies assessed virological outcomes at six months of maintenance therapy, whereas ten of them additionally showed outcomes at one year ^[@ref-8],\ [@ref-11],\ [@ref-12],\ [@ref-24],\ [@ref-27],\ [@ref-29]--\ [@ref-33],\ [@ref-35]^. Two studies assessed virological outcomes only at 48 weeks ^[@ref-25],\ [@ref-27]^. Median (or mean) age of participants included in the studies varied from 43 years ^[@ref-11]^ to 63 years ^[@ref-24]^ and 27.6% of them were female. 16 studies reported on the median nadir CD4 cell count, which ranged from 90 cells/µl ^[@ref-12]^ to 399 cells/µl ^[@ref-29]^.

![Flow chart of study selection process.](f1000research-7-19875-g0000){#f1}

###### Study characteristics, by treatment group.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                   Country   Patients\   Median/\    Female\   VF definition       Study\   Eligibility criteria                                          
                                    included\   mean age\   (%)                           type                                                                   
                                    (N)         (years)                                                                                                          
  ----------------------- --------- ----------- ----------- --------- ------------------- -------- ---------------------- --------------- ------- ------ ------- ---------------------------------------------------
  **[DTG-Mono]{.ul}**                                                                                                                                            

  Katlama *et al*.\       F         28          48          46.4      2× ≥ 50 cp/ml or\   O        Yes                    \-              \-      ≥ 12   \-      \-
  *JAC 2016*                                                          1× \> 200 cp/ml                                                                            

  Wijting *et al*.\       NL        96          45.5        8.5       2× ≥ 200 cp/ml      I        No                     No              \-      ≥ 6    \>200   VL zenith \<100.000
  *Lancet HIV*                                                                                                                                                   

  Gubavu *et al*.\        F         21          47          38        2× ≥ 50 cp/ml       O        Yes                    \-              \-      \-     \-      \-
  *JAC 2016*                                                                                                                                                     

  Oldenbüttel *et al*.\   D         31          44.5        32        2× ≥ 20 cp/ml       O        Yes                    Not to InSTI    \-      ≥ 6    \-      no AIDS history
  *AVT 2016*                                                                                                                                                     

  Rokx *et al*.\          NL        5           63          0         2× ≥ 50 cp/ml       I        Yes                    \-              \-      ≥ 12   \-      \-
  *JAC 2016*                                                                                                                                                     

  Rojas *et al*.\         E         31          56          55        2× ≥ 37 cp/ml       O        Yes                    \-              \-      \-     \-      \-
  *JAC 2016*                                                                                                                                                     

  Lecompte *et al*.\      CH        8           44.5        28.5      1× ≥ 200cp/ml       I        No                     No              ≥ 24    \-     \-      \-
  *IAS 2017*                                                                                                                                                     

  Blanco *et al*.\        E         31          47          10        2× ≥ 50 cp/ml or\   I        Yes                    \-              \-      ≥ 12   \>200   \-
  *JAC 2018*                                                          1× \> 1000 cp/ml                                                                           

  **[DTG-3TC]{.ul}**                                                                                                                                             

  Borghetti *et al*.\     I         36          53          19.4      2× ≥ 50 cp/ml       O        Yes                    \-              \-             \-      \-
  *JAC 2016*                                                                                                                                                     

  Maggiolo *et al*.\      I         94          52          32.3      2× ≥ 50 cp/ml       O        Yes                    Not to 3TC\     \> 6    ≥ 6    \-      \-
  *BMC ID 2017*                                                                                                           or InSTI                               

  Joly *et al*.\          F         104         45          14.4      2× ≥ 50 cp/ml       I        No                     No              \-      ≥ 24   \>200   no HIV encephalitis ^[£](#TF1){ref-type="other"}^
  *CROI 2017*                                                                                                                                                    

  Reynes *et al*.\        F         27          59          25.9      2× ≥ 50 cp/ml       O        Yes                    Not to InSTI    \> 12   \-     \-      \-
  *HIV Glasgow*\                                                                                                                                                 
  *2016*                                                                                                                                                         

  Blanco *et al*.\        E         29          44          21                            I        Yes                    \-              \-      ≥ 12   \>200   \-
  *JAC 2018*                                                                                                                                                     

  Maggiolo *et al*.\      I         203         52          24.6      \-                  O        Yes                    No M184V        \-      ≥ 6    \-      \-
  *EACS 2017*                                                                                                                                                    

  Taiwo *et al*.\         US        44          46          17        2× ≥ 50 cp/ml       I        No                     No              ≥ 12    ≥ 12           
  *CID 2017*                                                                                                                                                     

  **[DTG-RPV]{.ul}**                                                                                                                                             

  Llibre *et al*.\        Multi-\   513         43          23        1× ≥ 50 cp/ml       I        No                     \-              \> 6    ≥ 12   \-      \-
  *Lancet 2018*           country                                                                                                                                

  Gantner *et al*.\       F         116         55          44        2× ≥ 50 cp/ml or\   O        Yes                    \-              \-      \-     \-      \-
  *HIV Med 2017*                                                      1× ≥ 1,000 cp/ml                                                                           

  Bonijoly *et al*.\      F         268         55          44        2× ≥ 50 cp/ml       O        Yes                    \-              \-      ≥ 6    \-      On ART for ≥ 12\
  *EACS 2017*                                                                                                                                                    months

  Revuelta *et al*.\      E         32          49          37        2× ≥ 50 cp/ml       O        Yes                    Not to InSTI\   \-      \-     \-      \-
  *Ann pharmacol*\                                                                                                        or RPV                                 
  *2018*                                                                                                                                                         

  **[DTG-ATV]{.ul}**                                                                                                                                             

  Riva *et al*.\          I         61          52.1        39        \-                  O        \-                     \-              \-      \-     \-      \-
  *HIV Glasgow*\                                                                                                                                                 
  *2016*                                                                                                                                                         

  Castagna *et al*.\      I         116         53          13        2× ≥ 50 cp/ml       O        \-                     \-              \-      ≥ 12   \-      \-
  *EACS 2017*                                                                                                                                                    

  **[DTG-DRV]{.ul}**                                                                                                                                             

  Navarro *et al*.\       E         27          52          30        2× ≥ 50 cp/ml       O        Yes                    Only to one\    \-      ≥ 6    \-      \-
  *EACS 2017*                                                                                                             ART class                              
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: VF: virologic failure, ART: antiretroviral therapy, DTG: dolutegravir, 3TC: lamivudine, FTC: emtricitabine, RPV: rilpivirine, ATV: atazanavir, InSTI: integrase stand transfert inhibitor, F: France, NL: The Netherlands, D: Germany, E: Spain, CH: Switzerland, I: Italy, USA: United States of America, O: observational study; I: interventional study

£:      no abnormal standard biological parameter

Risk of bias
------------

All RCTs were open-label non-inferiority trials ^[@ref-8],\ [@ref-18],\ [@ref-35]^, of which one was a single center trial ^[@ref-18]^ and three were multicenter trials ^[@ref-8],\ [@ref-11],\ [@ref-35]^. They reported adequate generation of random allocation sequences and allocation concealment. Three single-arm trials were included, of which two included less than 10 patients ^[@ref-21],\ [@ref-24],\ [@ref-29]^. All interventional studies adequately addressed incomplete outcome data: proportions of drop-outs were low and outcome data were missing for less than 20% of participants in all studies. Five of seven trials reported on virological outcomes at both time-points of interest for this study (24 and 48 weeks) ^[@ref-8],\ [@ref-11],\ [@ref-24],\ [@ref-29],\ [@ref-35]^. There was no evidence of selective reporting in any of the studies. In each of the 14 observational studies included in this review, the main demographic and clinical characteristics of the study populations were similar and patients were followed for 24 weeks in most studies. Among the observational studies, the majority did not report detailed inclusion and exclusion criteria. Five observational studies reported virological outcomes at both time-points ^[@ref-12],\ [@ref-30]--\ [@ref-33]^. Amplification for drug resistance testing was successful for 19 of the 27 (70%) patients with VF. Finally, patient retention was over 90% in all 14 cohort studies.

Virological and treatment failure
---------------------------------

The pooled estimate of the proportion of participants who experienced a VF on DTG-based monotherapy was 3.6% (95% CI 1.9-6.7) at 24 weeks and 8.9% (95% CI 4.7-16.2) at 48 weeks ( [Figure 2](#f2){ref-type="fig"}). The high proportion of treatment failures among patients on monotherapy at 48 weeks was driven by the two studies from the Netherlands, which observed between 8 and 20% of VF ^[@ref-8],\ [@ref-24]^. Among patients on dual therapy, an estimated 0.4% (95% CI 0.2-0.9) experienced a VF at 24 weeks and 0.7% (95% CI 0.4-1.3) at 48 weeks. Independently of the combination used (DTG/3TC, DTG/RPV, DTG/ATV or DTG/DRV), 11 of 14 studies evaluating the effectiveness of dual therapy had less than 1% of patients developing VF. Compared to patients on monotherapy, those on dual therapy were less likely to experience VF by 24 weeks (odds ratio \[OR\] 0.10, 95% CI 0.03-0.32, p\<0.001) and 48 weeks (OR 0.07, 95% CI 0.03-0.18, p\<0.001). In analyses adjusted for study type (interventional or observational), age (median or mean) and sex (proportion of female participants), the OR for VF at 24 weeks and 48 weeks were very similar to the unadjusted estimates (aOR 0.10, 95% CI 0.03-0.30 for 24 weeks and aOR 0.06, 95% CI 0.01-0.30 for 48 weeks, respectively). The only variable that contributed to explaining the between-study heterogeneity in both the 24 and 48-week analyses was treatment strategy. When including this variable, the tau-squared were reduced from 1.17 (95% CI 0.33-2.19) to 0.00 (95% CI 0.00-1.11) in the 24 week analysis and from 1.37 (95% CI 0.54-2.15) to 0.00 (95% CI 0.00-1.00) in the 48 week analysis. The inclusion of other variables did not impact the estimates of tau-squared.

![Meta-analysis of virological failure among patients on single or dual DTG-based simplification therapy.](f1000research-7-19875-g0001){#f2}

Treatment failure occurred in 5.2% (2.0--12.9) of patients at 24 weeks and 12.3% (4.5--29.4) at 48 weeks on DTG-monotherapy, whereas this outcome was observed in 2.8% (1.4--5.7) of patients at 24 weeks and 6.5% (4.3--9.6) at 48 weeks on DTG-based dual therapy. At 24 weeks, patients on dual therapy tended to be less likely to experience treatment failure compared to those on monotherapy (aOR 0.52, 95% CI 0.15-1.85). Due to multi-collinearity in the model, we were not able to report on multivariable analyses comparing treatment failure between mono and dual therapy at 48 weeks.

Drug resistance
---------------

Acquired resistance mutations to InSTI developed in 9/251 (3.6%) participants on DTG-based monotherapy, which corresponded to 56% of the cases of VF ( [Table 2](#T2){ref-type="table"}). Three individuals developed the Q148R or Q148H mutation in combination with other resistance mutations, conferring high-level resistance to DTG ^[@ref-20],\ [@ref-22]^. Two of these three patients were previously exposed to InSTI and none had a history of previous VF. They all had a suppressed HIV viral load for several years before switching to DTG-monotherapy. No InSTI resistance mutations developed in patients on dual therapy. Of 962 patients on RPV/DTG, only one developed a major drug resistance mutation to non-nucleoside reverse transcriptase inhibitors (K101E). No resistance was observed in plasma among 237 individuals on DTG/3TC.

###### Virological outcomes and drug resistance, by study.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                 Follow-up\   N°\        [N° treatment]{.ul}\   [N° virological]{.ul}\   N°\         N° patients\   Resistance patterns\                                 
                        (weeks)      patients   [failures (%)]{.ul}    [failures (%)]{.ul}      amplified   with\          (one line\                                           
                                                                                                            resistance     per patient) [\*](#TFN2){ref-type="other"}           
  --------------------- ------------ ---------- ---------------------- ------------------------ ----------- -------------- -------------------------------------------- ------- -----------------------------------------------------------------------------------
  **[DTG-Mono]{.ul}**                                                                                                                                                           

  Katlama *et al*.      24           28         4 (14.3)               \-                       3 (10.7)    \-             3                                            **3**   **E138K,G140A, Q148R**\
                                                                                                                                                                                **E92Q**\
                                                                                                                                                                                **N155H**

  Wijting *et al*.      48           96         \-                     11 (11.5)                2 (2.1)     8 (8.3)        6                                            **3**   **S230R**\
                                                                                                                                                                                **R263K**\
                                                                                                                                                                                **N155H**

  Gubavu *et al*.       24           21         0                      \-                       0           \-             \-                                           \-      

  Oldenbüttel\          24           31         2 (6.5)                \-                       1 (3.2)     \-             1                                            **1**   **Q148H, G140S**
  *et al*.                                                                                                                                                                      

  Rokx *et al*.         48           5          0                      1 (20)                   0           1 (20.0)       1                                            0       

  Rojas *et al*.        24           31         1 (3.2)                \-                       1 (3.2)     \-             1                                            0       118R [\*\*](#TFN3){ref-type="other"}

  Lecompte *et al*.     24           8          1 (12.5)               \-                       0           \-             \-                                           \-      

  Blanco *et al*.       24           31         2 (6.5)                \-                       2 (6.4)     \-             2                                            **2**   **E138A, S147G, N155H,**\
                                                                                                                                                                                **Q148R**\
                                                                                                                                                                                **138K, 155H, 140S**

  **[DTG-3TC]{.ul}**                                                                                                                                                            

  Borghetti *et al*.    24           36         3 (8.3)                \-                       0           \-             \-                                           \-      

  Maggiolo *et al*.     48           94         0                      3 (3.2)                  0           0              \-                                           \-      

  Joly *et al*.         48           104        1 (1.0)                3 (2.9)                  1 (1.0)     1 (1.0)        0                                            \-      

  Reynes *et al*.       48           27         3 (11.1)               3 (11.1)                 0           0              \-                                           \-      

  Blanco *et al*.       24           29         1 (3.5)                \-                       1 (3.4)     \-             1                                            0       K70E [\*\*\*](#TFN4){ref-type="other"}, K219E [\*\*\*](#TFN4){ref-type="other"},\
                                                                                                                                                                                G190R ^[\$](#TFN5){ref-type="other"}^, M230I ^[\$](#TFN5){ref-type="other"}^

  Maggiolo *et al*.     48           203        0                      12 (6.0)                 0           0              \-                                           \-      

  Taiwo *et al*.        48           44         1 (2.3)                3 (6.9)                  1           1              1                                            0       

  **[DTG-RPV]{.ul}**                                                                                                                                                            

  Llibre *et al*.       48           513        \-                     27 (5.3)                 1 (0.2)     2 (0.4)        2                                            1       K101K/E

  Gantner *et al*.      24           116        11 (9.5)               \-                       1 (0.9)     \-             0                                            \-      

  Bonijoly *et al*.     24           268        \-                     51 (19.0)                \-          4 (1.5)        \-                                           \-      

  Revuelta *et al*.     48           32         \-                     2 (6.5)                  0           0              \-                                           \-      

  **[DTG-ATV]{.ul}**                                                                                                                                                            

  Riva *et al*.         24           61         3 (4.9)                \-                       0           \-             \-                                           \-      

  Castagna *et al*.     48           116        5 (4.3)                6 (5.2)                  \-          1 (0.9)        \-                                           \-      

  **[DTG-DRV]{.ul}**                                                                                                                                                            

  Navarro *et al*.      48           27         \-                     2 (7.4)                  0           1 (3.7)        1                                            0       
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*bold: InSTI resistance

\*\*in 7% of integrated DNA in PBMC

\*\*\* in ≤1.5% of integrated DNA in PBMC

^\$^ in integrated DNA in PBMC

###### 

This table shows summary measures, including the number of virological and treatment failures in each study.

###### 

Click here for additional data file.
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Discussion
==========

We performed a comprehensive systematic review of studies that reported on VF among patients switched to DTG-based maintenance therapy. Our meta-analysis shows that DTG-based dual therapy is successful in sustaining virological control in ART-experienced HIV-infected patients: only 12 of 1670 (0.7%) experienced a VF and none of them developed resistance mutations to DTG. On the contrary, 16 of 251 (6.4%) individuals switched to DTG monotherapy had a VF, of which more than one-half developed resistance to DTG. In comparison, recent trials evaluating InSTI-based triple maintenance combinations showed a similar virological failure rates ^[@ref-36],\ [@ref-37]^. Although the proportion of patients experiencing a confirmed viral rebound on DTG-monotherapy does not seem to be higher than in patients on PI-monotherapy, the risk of losing future treatment options is higher with DTG-monotherapy ^[@ref-3]^. Overall, our findings suggest that DTG-based monotherapy is not an appropriate simplification strategy and that further studies are urgently needed to confirm the long-term efficacy of DTG-based dual therapy.

DTG-based dual therapy is a promising simplification strategy, especially when combined with 3TC, as the likelihood of developing toxicity events and DDI on such regimens is very low. No drug resistance mutations to DTG developed among more than 1600 patients on dual therapy followed for 24 to 48 weeks and only one had a resistance mutation to another drug class. Although based on very few patients, the results seemed to be independent of previous virological failures. For instance, no virological failures were noted among patients on DTG/3TC despite the presence of a 184V mutation at the time of simplification in several studies. The impact of the latter mutation on viral fitness has been extensively described both *in vitro* ^[@ref-38]^ and *in vivo* ^[@ref-39]^, and could also potentially explain the improved treatment outcomes in these patients compared to those switched to DTG-monotherapy without any previous failures. Interestingly, similar observations were made for bPI-based regimens, for which efficacy was improved when 3TC was added, despite the presence of the 184V mutation ^[@ref-39]^.

We also report on estimates of treatment failure, which includes other reasons for treatment interruptions, such as toxicity or loss to follow-up. In our meta-analysis, the proportion of patients experiencing this combined outcome was more than twice as high among patients on monotherapy compared to those on DTG-based dual therapy. Although this outcome is important in evaluating the clinical efficacy of a novel ART strategy, our capacity to analyze this outcome in detail was limited by the missing information on the specific reasons for treatment interruptions in many studies and by the small number of events, especially at 48 weeks of therapy.

Of all simplification strategies evaluated to date, the DTG/3TC combination could be the one most readily accessible for patients in low- and middle-income countries: both DTG and 3TC are available and prequalified by stringent regulatory authorities in generic formulations. In order to be widely implemented, the efficacy of this dual combination should first be evaluated in large studies among different patient populations. The results from the studies included in our meta-analysis are mainly based on selected populations of HIV-infected individuals from European cohorts, and are not generalizable. Furthermore, long-term data are needed, as most treatment failures occurred after the first 24 weeks in several monotherapy studies. Recently, results from the only study which assessed 96-week outcomes with this regimen to date were reported: among 27 ART-experienced individuals with previous VF, DTG/3TC was 100% efficacious virologically ^[@ref-12]^. However, despite these encouraging results, data from larger studies are needed. In addition, more data on the activity of DTG-based simplified regimens in compartments other than blood are needed. Letendre *et al*. showed that DTG achieved therapeutic concentrations in the central nervous system (CNS), with a CNS penetration effectiveness score of four ^[@ref-40]^. In the MONODO study, all patients had an undetectable plasma HIV viral load at week 24 on DTG maintenance monotherapy, whereas only one had a detectable viral load in the cerebrospinal fluid ^[@ref-21]^. Moreover, levels of HIV-RNA in the genital tract on DTG monotherapy ^[@ref-41]^ and on DTG-3TC ^[@ref-42]^ were comparable to those on standard cART. However, these results were based on a very small sample of patients and data from individuals on simplified, DTG-based therapies are lacking.

As a wealth of data on the efficacy of DTG-maintenance strategies from small studies are being disseminated at a fast pace, this systematic review is the first analysis to provide comparative estimates of virological failure between DTG-based monotherapy and dual therapy. More than 1700 studies were screened, including abstracts from all important HIV conferences in the past years. As our meta-analysis included studies with diverse study designs and populations, it could be argued that the comparison of studies with such differences might be problematic. However, the estimates of VF were very similar across studies, especially in the DTG-based dual therapy arm. This finding highlights the potency of this combination, even in the presence of previous drug resistance mutations or multiple co-morbidities. Unfortunately, only studies including low numbers of patients reported outcomes from individuals on DTG-monotherapy, and data on dual therapy was dominated by one large study that assessed the efficacy of the DTG/RPV combination. As a consequence, the comparison of DTG-monotherapy vs. DTG/3TC, which would have been the most interesting one, was not possible. Furthermore, the lack of availability of individual data from the different studies precluded the analysis of risk factors of VF in the different simplification regimens. As most studies were observational, it is possible that the investigators mainly included patients with good adherence, which may have limited the generalizability of their findings. Finally, our results might have slightly under-estimated the proportion of patients with VF as individuals who were lost to follow-up might have experienced this outcome without them being accounted for. However, our treatment failure estimates showed that even when other reasons of treatment failure were considered, DTG-based dual therapy was superior to monotherapy.

In summary, DTG-based dual maintenance therapy seems to be a promising simplification strategy with high virological efficacy and low potential for DDI and toxicity. Such a treatment regimen could be an interesting alternative to classical triple-ART in selected patients. Furthermore, dual therapy might be a cost-effective global ART strategy ^[@ref-43]^. A number of large prospective studies evaluating the efficacy of DTG-based dual therapy are under way and will inform its potential implementation at a large scale. In addition to the studies using DTG-emtricitabine(FTC ^[@ref-44]^) and DTG-3TC ^[@ref-45]^ maintenance therapy, clinical trials are also assessing the efficacy of DTG/3TC in treatment-naïve patients ^[@ref-46]^. Furthermore, it will be critical to evaluate the efficacy of DTG-3TC or FTC dual therapy in specific sub-groups such as pregnant and breast-feeding women, adolescents, patients with previous failure to standard triple regimens and harboring the M184V resistance mutation, as well as in patients with HIV associated neurocognitive disorder and tuberculosis coinfection.

Data availability
=================

The data referenced by this article are under copyright with the following copyright statement: Copyright: © 2019 Wandeler G et al.

Data associated with the article are available under the terms of the Creative Commons Zero \"No rights reserved\" data waiver (CC0 1.0 Public domain dedication). <http://creativecommons.org/publicdomain/zero/1.0/>

F1000Research: Dataset 1. Dolutegravir meta-analysis summary data. [10.5256/f1000research.15995.d215724](https://doi.org/10.5256/f1000research.15995.d215724) ^[@ref-47]^
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The topic is extremely important, the conclusion is very relevant for informing the clinical practice and the timing is perfect. 

Please see below some comments to improve this excellent systematic review Note that reference 9 is for naive patients, and not for switching. REPRODUCIBILITY: Risk of bias checklist is not available. It could be good idea to include as supplementary material a sample of the checklist of assessment of bias. The number of reviewed studies is 21, but the authors reported 8 for monotherapy and 14 for dual therapy without clarifying that some are focused on both strategies.Similarly, in figure 2, the name of the author is followed by the (n) of participants. This makes the reader think this is the reference. Please consider to add the reference number in this place, and an additional column for \"n\"Regarding the phrase \"These three patients did not have a history of previous VF and had a suppressed HIV viral load for several years before switching to DTG-monotherapy\". Please comment if patients experiencing INSTI resistance in monotherapy were previously exposed to INSTI. Please review Table 2, because some INSTI mutations are not in bold, and the \$ symbol is not explained in notesIn discussion you mention \"For instance, no virological failures were noted among patients on DTG/3TC despite the presence of a 184V mutation at the time of simplification in several studies.\" but you are not showing this result. Given the potential clinical importance of this issue, consider show how many participants had this mutation and show the outcomes.In the discussion, these phrases look similar: First Paragraph: \"Although the proportion of patients experiencing a confirmed viral rebound on DTG-monotherapy does not seem to be higher than in patients on PI-monotherapy, the risk of losing future treatment options is higher with DTG-monotherapy\"Second Paragraph \"Although the proportion of patients experiencing a confirmed viral rebound on DTG-monotherapy does not seem to be higher than in patients on PI-monotherapy, their chances of losing future treatment options is higher than reported in most PI-monotherapy trials\" Why to mention DTG-XTC if no study was presented with FTC?. I would suggest to stick to the presented data, therefore to discuss about 3TC.  The phrase \"In addition to the studies on maintenance therapy ^[39](https://f1000research.com/my/referee/report/37756#ref-39),\ [40](https://f1000research.com/my/referee/report/37756#ref-40)^, clinical trials are also assessing the efficacy of DTG/XTC in treatment-naïve patients\" should be updated based on the results of GEMINI1&2.It could be good to try to explain the higher rate of failure in those three trials in dual therapy (Blanco, and Navarro). Please check the failure rate in figure 2 for Taiwo (44 patients with failure 2.7%).

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Wandeler

Gilles

Bern University Hospital, Switzerland

**Competing interests:**No competing interests were disclosed.

3

2

2019

Note that reference 9 is for naive patients, and not for switching.

*We agree with the comment. However, we prefer to keep this unchanged as we used the reference in a generic sentence.*

REPRODUCIBILITY: Risk of bias checklist is not available. It could be good idea to include as supplementary material a sample of the checklist of assessment of bias.

*We used the Cochrane Collaboration list to assess risk of bias among the two RCT included in the meta-analysis. For observational studies, it was not appropriate to use the ROBINS-I tool, as we only considered data from the group of patients maintenance therapy. Thus, we assessed the population characteristics and missing outcome data for each study. This is explained in detail in the methods section of the published manuscript.*

The number of reviewed studies is 21, but the authors reported 8 for monotherapy and 14 for dual therapy without clarifying that some are focused on both strategies.

*We explained this in the text (see data analysis section).*

Similarly, in figure 2, the name of the author is followed by the (n) of participants. This makes the reader think this is the reference. Please consider to add the reference number in this place, and an additional column for \"n\"

*The reference is indicated differently in the text and we decided to keep the figure 2 unchanged.*

Regarding the phrase (page 9) \"These three patients did not have a history of previous VF and had a suppressed HIV viral load for several years before switching to DTG-monotherapy\". Please comment if patients experiencing INSTI resistance in monotherapy were previously exposed to INSTI.

*We included this information in the new version of the paper (see drug resistance section).*

Please review Table 2, because some INSTI mutations are not in bold, and the \$ symbol is not explained in notes

*We adapted the table 2 in the new version of the paper.*

In discussion you mention \"For instance, no virological failures were noted among patients on DTG/3TC despite the presence of a 184V mutation at the time of simplification in several studies.\" but you are not showing this result. Given the potential clinical importance of this issue, consider show how many participants had this mutation and show the outcomes.

*As this information was missing from most studies, we described cases where reported but could not formally evaluate the association between specific mutations and treatment failure.*

In the discussion, these phrases look similar:

First Paragraph: \"Although the proportion of patients experiencing a confirmed viral rebound on DTG-monotherapy does not seem to be higher than in patients on PI-monotherapy, the risk of losing future treatment options is higher with DTG-monotherapy\"

Second Paragraph \"Although the proportion of patients experiencing a confirmed viral rebound on DTG-monotherapy does not seem to be higher than in patients on PI-monotherapy, their chances of losing future treatment options is higher than reported in most PI-monotherapy trials\"

*Adapted in the text (doubled sentence cancelled from the 2nd paragraph of the discussion section).*

Why to mention DTG-XTC if no study was presented with FTC?. I would suggest to stick to the presented data, therefore to discuss about 3TC.

*Adapted in the new version of the paper (see discussion section): XTC canceled and FTC used in reference to study using FTC.*

*The phrase \"In addition to the studies on maintenance therapy [39](https://f1000research.com/my/referee/report/37756#ref-39), [40](https://f1000research.com/my/referee/report/37756#ref-40), clinical trials are also assessing the efficacy of DTG/XTC in treatment-naïve patients\" should be updated based on the results of GEMINI1&2.*

*Adapted in the new version of the paper (see discussion section)*

It could be good to try to explain the higher rate of failure in those three trials in dual therapy (Blanco, and Navarro).

*This is an important comment. However, available data within these studies did not allow us to make specific conclusions.*

*Blanco dual: 3.45% VF at W24.*

*Bonijoly: 1.49% VF at W48.*

*Navarro: 3.70% of VF at W48.*

*Taiwo: 2.27% VF at W 24 and W48*

*All others dual \< 1% of VF both at 24 and 48 weeks.*

Please check the failure rate in figure 2 for Taiwo (44 patients with failure 2.7%).

*We checked again data and did not find any error in the figure.*

*Only one of the 44 patients exposed to dual therapy had a rel VF (1/44 0 2.7%). with the FDA snapshot algorithm 2 other patients (one lost to FUP and one switching therapy because AE) were considered as failure by authors at W24.*
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Wandeler and colleagues provide here an excellent and comprehensive review on DTG-based maintenance therapy, even though this review will lack the latest communications on the topic (at IAS 2018). Nevertheless, the conclusions they make are in accordance with what is currently admitted by experts in the field and worldwide guidelines: DTG monotherapy lead to an unacceptable virologic failure (VF) rate (because of \>50% of emerging mutations to the class) whereas dual therapy has an excellent efficacy and no VF with mutations to the class.

I only have minor comments or questions:

Results: (page 4) Can the authors provide any data on the impact of CD4 nadir on VF during monotherapy (as described by Wijting in the DOMONO trial)?(page 8) Authors should give more explicit conclusion on this paragraph "The only variable that contributed to explaining the between-study heterogeneity in both the 24 and 48-week analyses was treatment strategy. When including this variable, the tau-squared were reduced from 1.17 (95% CI 0.33-2.19) to 0.00 (95% CI 0.00-1.11) in the 24 week analysis and from 1.37 (95% CI 0.54-2.15) to 0.00 (95% CI 0.00-1.00) in the 48 week analysis. The inclusion of other variables did not impact the estimates of tau-squared." Discussion: (page 9) Please provide some references (at least one) for the impact of M184V on viral fitness (this one is of interest for DTG-based regimen: doi: 10.1097/QAD.0000000000001191)(page 9) I think authors should provide some data on VF (%, emerging mutations) during switch from a triple therapy to another one (in order to have an "historical comparator" for dual therapy)(page 10, "In addition, more data on the activity of DTG-based simplified regimens in compartments other than blood are needed.") There are some references for mono- or dual-therapy in the genital tract (Hocqueloux et al. ^[@rep-ref-37757-1]^ and Gianella et al. ^[@rep-ref-37757-2]^)and CNS (Doco Lecompte et al. ^[@rep-ref-37757-3]^)(page 10) Authors should cite recent reports (all communicated at the IAS 2018 in Amsterdam) confirming their conclusions, even though they cannot include them in the analyses: two randomized-controlled clinical trials on DTG monotherapy (Braun et al. ^[@rep-ref-37757-4]^ and Hocqueloux et al. ^[@rep-ref-37757-5]^), the extended follow-up of the SWORD trials at week 100 (Aboud et al. ^[@rep-ref-37757-6]^) and results of the GEMINI trials (Cahn et al. ^[@rep-ref-37757-7]^ ). References: (references 25 and 28) I think two references (Gantner and Bonijoly) are duplicates (as they are based on the analyze of the same database; Bonijoly et al. have included more patients / with longer duration of follow-up than Gantner).
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(page 4) Can the authors provide any data on the impact of CD4 nadir on VF during monotherapy (as described by Wijting in the DOMONO trial)?

*Unfortunately, we do not have these data from most of the studies.*

(page 8) Authors should give more explicit conclusion on this paragraph "The only variable that contributed to explaining the between-study heterogeneity in both the 24 and 48-week analyses was treatment strategy. When including this variable, the tau-squared were reduced from 1.17 (95% CI 0.33-2.19) to 0.00 (95% CI 0.00-1.11) in the 24 week analysis and from 1.37 (95% CI 0.54-2.15) to 0.00 (95% CI 0.00-1.00) in the 48 week analysis. The inclusion of other variables did not impact the estimates of tau-squared."

*The first sentence says explicitly that only the treatment strategy was found to contribute to heterogeneity, and we are not sure how to make the conclusion more explicit.*

*The second sentence quantifies the statement.*

(page 9) Please provide some references (at least one) for the impact of M184V on viral fitness (this one is of interest for DTG-based regimen: doi: 10.1097/QAD.0000000000001191)

*We included references in the new version of the paper (see 2 ^nd^ paragraph in the discussion section).* 

(page 9) I think authors should provide some data on VF (%, emerging mutations) during switch from a triple therapy to another one (in order to have an "historical comparator" for dual therapy)

*We added a comment in the 1st paragraph of the discussion section.*

*« We performed a comprehensive systematic review of studies that reported on VF among patients switched to DTG-based maintenance therapy. Our meta-analysis shows that DTG-based dual therapy is successful in sustaining virological control in ART-experienced HIV-infected patients: only 12 of 1670 (0.7%) experienced a VF and none of them developed resistance mutations to DTG. For comparison, recent trials testing InSTI-based triple maintenance combinations showed a similar virological failure rate (ref ci dessous 1-4). On the contrary, 16 of 251 (6.4%) individuals switched to DTG monotherapy had a VF, of which more than one-half developed resistance to DTG. »*

(page 10) "In addition, more data on the activity of DTG-based simplified regimens in compartments other than blood are needed." There are some references for mono- or dual-therapy in the genital tract (Hocqueloux et al. [1](https://f1000research.com/articles/7-1359/v1#rep-ref-37757-1) and Gianella et al. [2](https://f1000research.com/articles/7-1359/v1#rep-ref-37757-2)) and CNS (Doco Lecompte et al. [3](https://f1000research.com/articles/7-1359/v1#rep-ref-37757-3))

*We modified the text in the new version of the paper (see 4 ^th^ paragraph of the discussion section).*

« In addition, more data on the activity of DTG-based simplified regimens in compartments other than blood are needed. Letendre et al. Showed that DTG achieved therapeutic concentrations in the central nervous system (CNS), with a CNS penetration effectiveness

score of four. In the MONODO study, all patients had an undetectable plasma HIV viral load at week 24 on DTG maintenance monotherapy, whereas only one had a detectable viral load in the cerebrospinal fluid ( *ref 21 by Sculier et al*). Moreover, levels of HIV-1 RNA in the genital tract on DTG-monotherapy *(nouvelle ref 1 )* and under DTG-3TC *(nouvelle ref 2)*were comparable to those under standard cART. However, these results were based on a very small sample of patients and data from individuals on simplified, DTG-based therapies are lacking. »

*(*page 10) Authors should cite recent reports (all communicated at the IAS 2018 in Amsterdam) confirming their conclusions, even though they cannot include them in the analyses: two randomized-controlled clinical trials on DTG monotherapy (Braun et al. [4](https://f1000research.com/articles/7-1359/v1#rep-ref-37757-4) and Hocqueloux et al. [5](https://f1000research.com/articles/7-1359/v1#rep-ref-37757-5)), the extended follow-up of the SWORD trials at week 100 (Aboud et al. [6](https://f1000research.com/articles/7-1359/v1#rep-ref-37757-6)) and results of the GEMINI trials (Cahn et al. [7](https://f1000research.com/articles/7-1359/v1#rep-ref-37757-7)).

*In accordance  with the pre-specified analysis plan described in our study protocol, we decided not to include these results as they had not been presented at the time of the last version of our analyses.*

References: (references 25 and 28) I think two references (Gantner and Bonijoly) are duplicates (as they are based on the analyze of the same database; Bonijoly et al. have included more patients / with longer duration of follow-up than Gantner).

*We agree with the reviewer. However, as one study reported 24 weeks and the other 48 weeks outcomes, we decided to keep both estimates. Furthermore, we did not combine them as the study populations were not exactly the same.*
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This paper compared the efficacy of dolutegravir-based monotherapy vs dual therapy using the methodology of systematic review and meta-analysis. The topic is of great interest as many different studies with these simplication strategies have been done. Although dolutegravir monotherapy is not recommended at present due to the risk of virological failure with development of resistance mutations and dolutegravir dual therapy seems a promising strategy with recent evidence from large clinical trials, this systematic review and meta-analysis is timely because there are almost no direct comparisons between dolutegravir-based monotherapy vs dual therapy. The design and the methods (including PRISMA reporting) are adequate, as they are the interpretation of results. It is interesting that not only monotherapy was inferior to dual therapy but the difference resulted highly increased from 24 weeks to 48 weeks of follow-up, thus indicating that the risk of failure with the monotherapy strategy may greatly increase after the initial 24 weeks of follow-up. This is remarkable as many exploratory studies had 24-week results only.
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